Moderna faces shareholder pressure over cost of vaccine

Financial Times2021-12-27

Moderna explains why the price is so high given the amount of government-supported pharmaceutical groups fighting shareholder proposals calling for the release of Covid-19 vaccine technology to poor ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
5